A new emergency in oncology: Bone metastases in breast cancer patients (Review)
Open Access
- 4 June 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 6 (2) , 306-310
Abstract
Breast cancer (BC) is the most common tumour in females and as a result, the management of such patients is a major public health issue. A high percentage of BC patients develop bone metastases (BMs), occasionally even several years following the initial diagnosis. BMs are responsible for high morbidity and a reduced quality of life with the onset of various clinical complications defined as skeletal‑related events (SREs), including pathological fractures, spinal cord compression, hypercalcaemia, bone marrow infiltration and severe bone pain, requiring palliative radiotherapy. Such complications reduce functional independence and quality of life, decrease survival rates and increase healthcare costs. The current treatment for metastatic BC aims to achieve meaningful clinical responses, an improved quality of life, long‑term remission, prolonged survival and in a small percentage of cases, a complete cure. The treatment of this malignancy has become progressively complex, including well‑known antitumour agents or bone‑targeted molecules aimed at preventing bone complications and improving patient quality of life and the treatment outcome of a multidisciplinary programme. The importance of a multidisciplinary approach in the management of BMs is also widely accepted. The major complication of BMs are SREs which are responsible for reducing prognoses and patient quality of life and are correlated with high rates of hospitalisation with the subsequent social and economic consequences. For these reasons, it is crucial to prevent where possible or to identify and treat SREs promptly in an attempt to mitigate the ever‑increasing clinical and economic burden.Keywords
This publication has 32 references indexed in Scilit:
- Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectivesCritical Reviews in Oncology/Hematology, 2011
- Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer PatientsClinical Breast Cancer, 2011
- Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in DenmarkBMC Cancer, 2011
- Survival in Danish patients with breast cancer and inflammatory bowel disease: A nationwide cohort studyInflammatory Bowel Diseases, 2008
- New Tricks Against an Old Foe: Molecular Dissection of Metastasis Tissue Tropism in Breast CancerBreast Disease, 2007
- Tumor metastasis to boneArthritis Research & Therapy, 2007
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Osteoclast differentiation and activationNature, 2003
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of Clinical Oncology, 1998